BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25663551)

  • 1. Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.
    Mazzola R; Ferrera G; Alongi F; Mannino M; Abbate B; Cucchiara T; Iacoviello G; Sciumè F; Di Paola G; Federico M; Blasi L; Lo Casto A; Lagalla R; Messana D
    Radiol Med; 2015 Aug; 120(8):753-8. PubMed ID: 25663551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.
    Lambrecht M; Nevens D; Nuyts S
    Strahlenther Onkol; 2013 Mar; 189(3):223-9. PubMed ID: 23319256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
    Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
    Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique.
    Gensheimer MF; Nyflot M; Laramore GE; Liao JJ; Parvathaneni U
    Radiat Oncol; 2016 Nov; 11(1):151. PubMed ID: 27846899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
    Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
    Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
    Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
    Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
    Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
    Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation.
    Nangia S; Chufal KS; Arivazhagan V; Srinivas P; Tyagi A; Ghosh D
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):485-92. PubMed ID: 16909973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes.
    Miah AB; Schick U; Bhide SA; Guerrero-Urbano MT; Clark CH; Bidmead AM; Bodla S; Del Rosario L; Thway K; Wilson P; Newbold KL; Harrington KJ; Nutting CM
    Br J Cancer; 2015 Jan; 112(1):32-8. PubMed ID: 25474250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.